Bayesian Capital Management LP Lowers Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Bayesian Capital Management LP lowered its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 61.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,267 shares of the biopharmaceutical company’s stock after selling 71,800 shares during the quarter. Bayesian Capital Management LP’s holdings in TG Therapeutics were worth $673,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TGTX. Pingora Partners LLC acquired a new stake in TG Therapeutics in the fourth quarter valued at $27,000. Lazard Asset Management LLC acquired a new position in shares of TG Therapeutics during the 1st quarter worth $91,000. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 34.5% during the 4th quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,409 shares during the last quarter. Private Portfolio Partners LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth $201,000. Finally, Private Advisor Group LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth $233,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Down 3.0 %

TGTX traded down $0.60 during midday trading on Tuesday, hitting $19.21. The company’s stock had a trading volume of 2,797,817 shares, compared to its average volume of 3,639,109. The company has a current ratio of 3.62, a quick ratio of 2.84 and a debt-to-equity ratio of 0.63. TG Therapeutics, Inc. has a 52-week low of $6.46 and a 52-week high of $23.12. The firm has a market cap of $2.97 billion, a P/E ratio of 86.13 and a beta of 2.23. The firm has a 50-day moving average price of $18.28 and a two-hundred day moving average price of $16.41.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The firm had revenue of $63.47 million for the quarter, compared to analysts’ expectations of $54.60 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The firm’s revenue for the quarter was up 713.5% compared to the same quarter last year. On average, research analysts anticipate that TG Therapeutics, Inc. will post -0.01 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. LADENBURG THALM/SH SH boosted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, HC Wainwright boosted their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.83.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.